Lung Adenocarcinoma

A 45-year-old non-smoking female patient was diagnosed with a stage IV lung adenocarcinoma and magnetic resonance imaging showed multiple brain metastases. Targeted NGS analysis on the pleural biopsy … (full text at CIViC)

PMID 36419889 · Lazzari et al., 2022 · Open in CIViC

A patient with lung adenocarcinoma showed a double ALK fusion, EML6 exon1-ALK exon20 and FBXO11 exon1-ALK exon20. The patient received Crizotinib 250 mg twice daily and eventually showed partial respo… (full text at CIViC)

PMID 30368418 · Lin et al., 2018 · Open in CIViC

155 patients with lung adenocarcinomas underwent rebiopsy and genotyping (EGFR, AKT1, BRAF, ERBB2, KRAS, MEK1, NRAS, PIK3CA and FISH for MET and HER2) after the development of acquired resistance to E… (full text at CIViC)

PMID 23470965 · Yu et al., 2013 · Open in CIViC

A Phase II study for use of Afatinib in non- or light smokers with lung adenocarcinoma. Three patients with metastatic lung adenocarcinomas bearing mutations in the kinase domain of HER2 gene were ide… (full text at CIViC)

PMID 22325357 · De Grève et al., 2012 · Open in CIViC

A Phase II study for use of Afatinib in non- or light smokers with lung adenocarcinoma. Three patients with metastatic lung adenocarcinomas bearing mutations in the kinase domain of HER2 gene were ide… (full text at CIViC)

PMID 22325357 · De Grève et al., 2012 · Open in CIViC

In this phase II study (NCT00818441) of dacomitinib in HER2 amplified or mutant NSCLC tumors, three of 26 patients with HER2 p.P780_Y781insGSP or p.M774delinsWLV showed partial responses of duration b… (full text at CIViC)

PMID 25899785 · Kris et al., 2015 · Open in CIViC

The authors report a case series where one patient with lung adenocarcinoma harbored ERBB2 variant H878Y (exon 21). Case 2, a 59-year-old male, received Trastuzumab deruxtecan (T-DXd) (5.0 mg/kg once … (full text at CIViC)

PMID 40873587 · Meng et al., 2025 · Open in CIViC

A Phase II study for use of Afatinib in non- or light smokers with lung adenocarcinoma. Three patients with metastatic lung adenocarcinomas bearing mutations in the kinase domain of HER2 gene were ide… (full text at CIViC)

PMID 22325357 · De Grève et al., 2012 · Open in CIViC

This was a retrospective study of patients with advanced HER2-mutant NSCLC who had undergone varied courses of treatment. All tumors were adenocarcinoma with in-frame HER2 exon 20 insertions. In pat… (full text at CIViC)

PMID 26598547 · Mazières et al., 2016 · Open in CIViC

The authors report a case series where two patients with lung adenocarcinoma tumors harbored ERBB2 variant V659E (exon 17). Both cases achieved partial response to Trastuzumab deruxtecan (T-DXd). The… (full text at CIViC)

PMID 40873587 · Meng et al., 2025 · Open in CIViC

A 55 year old heavily pretreated patient with equivocal HER2 overexpression (IHC2+ and no amplification in FISH) was found to have the HER2 YMVA kinase domain insertion. Afatinib monotherapy resulted… (full text at CIViC)

PMID 26559459 · Li et al., 2015 · Open in CIViC

A Phase II study for use of Afatinib in non- or light smokers with lung adenocarcinoma. Three patients with metastatic lung adenocarcinomas bearing mutations in the kinase domain of HER2 gene were ide… (full text at CIViC)

PMID 22325357 · De Grève et al., 2012 · Open in CIViC

In this phase II study (NCT00818441) of dacomitinib in HER2 amplified or mutant NSCLC tumors, a cohort of 12 cases with the AYVM insertion did not show any partial responses to dacomitinib, in contras…

Study reporting an in-vivo two-stage initiation/promotion model, testing the hypothesis that Ereg deficiency would reduce lung tumor promotion in mice. Cancerogenesis with chemical initiators/promoter… (full text at CIViC)

PMID 26894620 · Bauer et al., 2017 · Open in CIViC

It is clear that patients with FGFR2/Plcγ1/Grb2 relative concentrations as: high/high/low have the poorest prognosis whilst those having FGFR2/Plcγ1/Grb2 as: low/low/high drastically enhances the prog… (full text at CIViC)

PMID 26693065 · Timsah et al., 2015 · Open in CIViC

FGFR3 G691R mutations were found in ~5.5% of lung adenocarcinoma patients using NGS and mass-spectrometry. The mutation was further found to transform NIH-3T3 cells and form tumors upon xenotransplant… (full text at CIViC)

PMID 27998968 · Chandrani et al., 2017 · Open in CIViC

In this study, 363 lung adenocarcinoma tumors of Indian origin were analyzed using targeted next-generation sequencing and mass spectrometry genotyping, and FGFR3 mutations were identified in 20 tumor… (full text at CIViC)

PMID 27998968 · Chandrani et al., 2017 · Open in CIViC

In a xenograft model, FGFR4 overexpressing HCC827 cells exhibited higher resistance to erlotinib. And also, H1975 cells showed resistance to erlotinib. The combination of erlotinib and FGFR1/2/3/4 inh… (full text at CIViC)

PMID 31027687 · Quintanal-Villalonga et al., 2019 · Open in CIViC

In a xenograft model, FGFR4 overexpressing HCC827 cells exhibited higher resistance to erlotinib. And also, H1975 cells showed resistance to erlotinib. The combination of erlotinib and FGFR1/2/3/4 inh… (full text at CIViC)

PMID 31027687 · Quintanal-Villalonga et al., 2019 · Open in CIViC

Targeting overactive GATA2-mediated pathways with inhibitors bortezomib and fasudil led to dramatic tumor regression.

PMID 22541434 · Kumar et al., 2012 · Open in CIViC

In a preclinical study in an immunocompetent mouse model of lung adenocarcinoma, upregulation of alternative immune checkpoints, notably T-cell immunoglobulin mucin-3 (TIM-3, aka HAVCR2) was observed … (full text at CIViC)

PMID 26883990 · Koyama et al., 2016 · Open in CIViC

In a preclinical study in an immunocompetent mouse model of lung adenocarcinoma, upregulation of alternative immune checkpoints, notably T-cell immunoglobulin mucin-3 (TIM-3, aka HAVCR2) was observed … (full text at CIViC)

PMID 26883990 · Koyama et al., 2016 · Open in CIViC

Comprehensive genomic profiling on a tumor and germline sample from a patient with refractory lung adenocarcinoma who achieved marked long-term clinical benefit from anti-PD-L1 therapy. Two activating… (full text at CIViC)

PMID 26014096 · Van Allen et al., 2015 · Open in CIViC

Comprehensive genomic profiling on a tumor and germline sample from a patient with refractory lung adenocarcinoma who achieved marked long-term clinical benefit from anti-PD-L1 therapy. Two activating… (full text at CIViC)

PMID 26014096 · Van Allen et al., 2015 · Open in CIViC

Case report of a 50-year-old male with Stage 1 Lung adenocarcinoma. NGS detected the presence of KIF5B::EGFR fusion (exon 15 and exon 18). The patient received two cycles of chemotherapy but experienc… (full text at CIViC)

PMID 34163176 · Wang et al., 2021 · Open in CIViC

This case study reports the first case of a KIF5B-EGFR fusion (KIF5B exon 15–EGFR exon 18) in primary lung adenocarcinoma. The patient showed a significant partial response to afatinib and bevacizumab… (full text at CIViC)

PMID 32903808 · Xu et al., 2020 · Open in CIViC

A 56 year old woman presents with poorly differentiated stage IIIC lung adenocarcinoma. Chemoradiotherapy and 12-month durvalumab was administered with significant response. 11 months after durvalumab… (full text at CIViC)

PMID 36033470 · Lin et al., 2022 · Open in CIViC

Case report of a 74-year old woman with EGFR- and ALK-negative lung adenocarcinoma. FISH identified a deletion of 5'RET (FISH, indicating RET-gene rearrangement) and genomic testing confirmed a fusion… (full text at CIViC)

PMID 25982012 · Subbiah et al., 2015 · Open in CIViC

A case study of a patient with EGFR, KRAS, BRAF, HER2, ALK, ROS1 and MET negative adenocarcinoma of the lung. FISH analysis revealed a KIF5B-RET fusion. The RET inhibitor Vandetanib led to remission i… (full text at CIViC)

PMID 23584301 · Gautschi et al., 2013 · Open in CIViC

In a stage IV lung adenocarcinoma patient harboring a KIT D816G mutation, the KIT D816G mutation was associated with crizotinib resistance. The patient was initially found to harbor a ROS1 gene rearra… (full text at CIViC)

PMID 27068398 · Dziadziuszko et al., 2016 · Open in CIViC

In preclinical lung adenocarcinoma (LUAD) models, loss-of-function KMT2D (truncating/inactivating) was associated with greater sensitivity to glycolysis inhibition, most consistently 2-deoxy-D-glucose… (full text at CIViC)

PMID 32243837 · Alam et al., 2020 · Open in CIViC

KRAS mutations (N=29 G12, N=1 G13) were the primary predictor of EGFR TKI resistance in patients with lung adenocarcinoma (N=83). Overall survival (P=0.001) and progression-free survival (P=0.005) wer… (full text at CIViC)

PMID 19794967 · Marchetti et al., 2009 · Open in CIViC

In two lung adenocarcinoma patients with EML4-ALK rearrangement (known to be sensitizing to crizotinib) and KRAS G12C co-mutation, progressive disease in response to 2nd-line crizotinib monotherapy wa… (full text at CIViC)

PMID 26712101 · Ulivi et al., 2016 · Open in CIViC

A 63 year old patient was diagnosed with lung adenocarcinoma and received several treatment regimens over approximately three years, including carboplatin/paclitaxel, erlotinib, pemetrexed/bevacizumab… (full text at CIViC)

PMID 23524406 · Rudin et al., 2013 · Open in CIViC

The use of NVP-BEZ235 in conjunction with ARRY-142886, but not as monotherapy, in a lung cancer mouse model with an inducible KRAS G12D mutation (lox-stop-lox KRAS G12D floxed via inhaled adenoviral C… (full text at CIViC)

PMID 19029981 · Engelman et al., 2008 · Open in CIViC

A 45-year old male (heavy smoker) presented with stage IV NSCLC (moderately differentiated adenocarcinoma. Sanger sequencing revealed a MET exon 14 splice site mutation (c.2888_3028del) and KRAS G12D … (full text at CIViC)

PMID 27257131 · Liu et al., 2016 · Open in CIViC

Following rapamycin treatment of mice with KrasG12D-induced lung adenocarcinomas, mice with Tsc1 deletion (exon17/18 deletion resulting in frameshift) in the lung exhibit increased overall survival, i… (full text at CIViC)

PMID 19966866 · Liang et al., 2010 · Open in CIViC

In a clinical study including 148 patients expressing KRAS mutants, low expression of KRAS4A is significantly associated with decreased OS (p = 2.72 x 10^-3) and low proportion of KRAS4A is also signi… (full text at CIViC)

PMID 29504894 · Yang et al., 2018 · Open in CIViC

In a study of 1036 patients with lung adenocarcinoma, patients with KRAS mutations (n=241) showed worse prognosis (OS: 19 months versus 23 months; HR=1.21; P=0.048).

PMID 22810899 · Johnson et al., 2013 · Open in CIViC

In a study of 30 lung adenocarcinoma patients with documented KRAS mutations, farnesylthiosalicylic acid (Salirasib) mono-therapy resulted in no partial responses and did not improve overall survival … (full text at CIViC)

PMID 21847063 · Riely et al., 2011 · Open in CIViC

In a retrospective LUAD cohort treated with PD-1 plus CTLA-4 blockade (n = 59; LRP1B-MT n = 15, LRP1B-WT n = 44), LRP1B-mutated tumors showed significantly longer PFS (log-rank p = 0.0016), along with… (full text at CIViC)

PMID 37057124 · He et al., 2023 · Open in CIViC

Xu et al. retrospectively analyzed paired pre- and post-EGFR tyrosine kinase inhibitor samples from 3,873 patients with EGFR-mutant lung adenocarcinoma and identified an acquired LRRC71::NTRK1 fusion … (full text at CIViC)

PMID 31372039 · Xu et al., 2019 · Open in CIViC

In a study of 6,024 lung adenocarcinomas, 36 conferred MEK1 mutations whereby 64% (n=23) were K57N and 19% (n=7) were Q56P. Median overall survival of MEK1-mutated tumors was not significantly differe… (full text at CIViC)

PMID 25351745 · Arcila et al., 2015 · Open in CIViC

Mutational profiling of 207 lung adenocarcinomas identified in 2 of with activating mutation in exon 2 of MEK1 (K57N) in the nonkinase portion of the kinase. Neither of these two tumors harbored known… (full text at CIViC)

PMID 18632602 · Marks et al., 2008 · Open in CIViC

In an evaluation of a patient with crizotinib-sensitive lung adenocarcinoma, an MET-Amplification was identified using CGP. The patient attained a reduction in the target lesions by 38.7%, and the pa… (full text at CIViC)

PMID 25922291 · Le et al., 2015 · Open in CIViC

A 72-year old woman (former smoker: 12 pack-years) with advanced lung adenocarcinoma received 250 mg of crizotinib twice daily after first line chemotherapy with carboplatin, pemetrexed, and maintenan… (full text at CIViC)

PMID 26791794 · Jorge et al., 2015 · Open in CIViC

Case report of a patient with MET amplification without high-level MET/CEP7 ratio, MET exon 14 mutation or overexpression who achieved rapid response to crizotinib.

A 76-year old male (non-smoker) presented with stage IV lung adenocarcinoma with metastatic disease in the lung and thoracic vertebra (T2). Next-generation sequencing revealed a MET exon 14 skipping m… (full text at CIViC)

PMID 27257131 · Liu et al., 2016 · Open in CIViC